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Background: Arterial calcification closely parallels osteoporosis in women. We and others have previously described a positive correlation between 
osteoprotegerin (OPG) levels, an inhibitor of bone resorption, and coronary artery calcification (CAC). We examined the relationship between levels 
of receptor activator of nuclear kappa-B (RANKL), an inducer of osteoclastogenesis, CAC and traditional cardiovascular (CV) risk factors (RF) in 2 
separate populations of postmenopausal women.
methods: OPG and RANKL levels were measured in stored blood samples from the Women on the Move through Activity and Nutrition (WOMAN) 
Study and the Healthy Women Study (HWS). In both populations, CAC score was measured by electron beam tomography in postmenopausal women 
4-8 years after menopause. OPG and RANKL levels were measured by ELISA.
results: A significant positive association was observed between OPG levels and CAC in the WOMAN Study (p<0.03) after adjustment for many CV 
RF and age. In the HWS, there was no relationship between OPG levels and CAC but a significant negative association between RANKL levels and 
CAC. RANKL levels in both populations were inversely related to the serum triglyceride (TG) levels. (Table) In the HWS, RANKL and triglycerides were 
independent predictors of CAC.
conclusions: This inverse association between RANKL and TG levels has not been reported. Further studies to replicate these observations with 
regard to drugs that modify osteoclast activity and coronary heart disease are needed.
 
